ATE255891T1 - Stabiles gabapentin, das mehr als 20 ppm chlor enthält - Google Patents

Stabiles gabapentin, das mehr als 20 ppm chlor enthält

Info

Publication number
ATE255891T1
ATE255891T1 AT01946364T AT01946364T ATE255891T1 AT E255891 T1 ATE255891 T1 AT E255891T1 AT 01946364 T AT01946364 T AT 01946364T AT 01946364 T AT01946364 T AT 01946364T AT E255891 T1 ATE255891 T1 AT E255891T1
Authority
AT
Austria
Prior art keywords
ppm chlorine
stable gabapentin
stable
gabapentin containing
ppm
Prior art date
Application number
AT01946364T
Other languages
English (en)
Inventor
Claude Singer
Gideon Pilarski
Michael Pesachovich
Edi Schwartz
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22788993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE255891(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE255891T1 publication Critical patent/ATE255891T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01946364T 2000-06-16 2001-06-15 Stabiles gabapentin, das mehr als 20 ppm chlor enthält ATE255891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21196700P 2000-06-16 2000-06-16
PCT/US2001/019100 WO2001097612A1 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion

Publications (1)

Publication Number Publication Date
ATE255891T1 true ATE255891T1 (de) 2003-12-15

Family

ID=22788993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946364T ATE255891T1 (de) 2000-06-16 2001-06-15 Stabiles gabapentin, das mehr als 20 ppm chlor enthält

Country Status (12)

Country Link
US (1) US6531509B2 (de)
EP (1) EP1289364B1 (de)
AT (1) ATE255891T1 (de)
AU (1) AU2001268426A1 (de)
CA (1) CA2410867C (de)
DE (2) DE60101476T2 (de)
DK (1) DK1289364T3 (de)
ES (1) ES2193008T3 (de)
IL (1) IL153398A0 (de)
PT (1) PT1289364E (de)
TR (1) TR200302296T4 (de)
WO (1) WO2001097612A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1447684A (zh) * 2000-06-16 2003-10-08 特瓦制药工业有限公司 具有在可控制范围内的pH值的稳定的加巴喷丁
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
KR20060108692A (ko) * 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN101462975B (zh) * 2008-08-19 2012-07-25 宁波九胜创新医药科技有限公司 一种高纯度加巴喷丁的制备方法
CN116693410B (zh) * 2023-06-08 2024-06-07 浙江竹子制药有限公司 一种粒径可控的加巴喷丁制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2611690A1 (de) 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US5132451A (en) 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
PH27359A (en) 1989-08-25 1993-06-21 Warner Lambert Co Process for cyclic amino acid anticonvulsant compounds
DE3928182A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
DE3928184A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
ID26395A (id) * 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
CA2327285C (en) * 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same

Also Published As

Publication number Publication date
DK1289364T3 (da) 2004-04-13
CA2410867A1 (en) 2001-12-27
WO2001097612A1 (en) 2001-12-27
ES2193008T1 (es) 2003-11-01
AU2001268426A1 (en) 2002-01-02
TR200302296T4 (tr) 2004-02-23
EP1289364B1 (de) 2003-12-10
EP1289364A4 (de) 2003-08-06
IL153398A0 (en) 2003-07-06
DE60101476D1 (de) 2004-01-22
PT1289364E (pt) 2004-04-30
DE1289364T1 (de) 2003-09-18
DE60101476T2 (de) 2004-05-27
US6531509B2 (en) 2003-03-11
US20020061931A1 (en) 2002-05-23
ES2193008T3 (es) 2004-07-01
EP1289364A1 (de) 2003-03-12
CA2410867C (en) 2003-12-09

Similar Documents

Publication Publication Date Title
DE60101476D1 (de) Stabiles gabapentin, das mehr als 20 ppm chlor enthält
ATE357902T1 (de) Zusammensetzungen enthaltend ein solubilisiertes säuereangereichtes antischweissmiteel
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
NO20014485L (no) Nye forbindelser og sammensetninger som proteaseinhibitorer
BR9809304A (pt) "formulações de proteìna c ativada"
BR0209020A (pt) Composição farmacêutica de polialilamina
SE9802729D0 (sv) Novel Compounds
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
NO20014101L (no) Stabilisert oral farmasöytisk blanding inneholdende iodid og iodat og fremgangsmåte
ATE262277T1 (de) Wasser-dispergierbare agrochemische zusammensetzungen
DE60238175D1 (de) Azeotrop-ähnliche zusammensetzung von 1,2-dichlor-
MX9707636A (es) Ascomicinas.
ATE393205T1 (de) Brausezusammensetzungen
MA27102A1 (fr) Composition pharmaceutique orodispersible d'ivabradine
DE60031439D1 (de) Verwendung von carboxy verbindungen wie 2(4-acetoxyphenyl)-2-chloro-n-methyl-ethylammonium chlorid als entzündungshemmende mittel
DK0937043T3 (da) Substituerede tetrahydropyridin-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse derivater
BR9611101A (pt) Composição cosmética transparente em bastão
BR0311590A (pt) Agonistas de brs-3 não-peptìdicos
DK1627037T3 (da) Blegende lugtreducerende chlorblegningssammensætning
IL159493A0 (en) Pharmaceutical formulation containing an ltb4 antagonist
ATE400580T1 (de) Chemische synthese von solamargin
ATE364594T1 (de) (4-acylaminopiperidin-1-yl)acetamide als neurokininantagonisten
UA36046A (uk) Антисептичний засіб
BR0115764A (pt) Composições, contendo copolìmeros à base de ácido acriloildimetiltaurìnico e aditivos sinergìsticos
RU2002120345A (ru) Средство "пипользин" антигистаминного действия

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1289364

Country of ref document: EP

RZN Patent revoked